In New England Journal of Medicine editorial, Fred Hutchinson Cancer Research Center’s Dr. Fred Appelbaum argues adult stem cells harvested from bone marrow rather than blood of unrelated donors are best for reducing graft-vs.-host disease risk
The molecular test is already saving lives of patients who relapse after bone-marrow or stem-cell transplantation. Researchers now predict that the approach will speed the delivery of promising new therapies to other patients
Fred Hutchinson Cancer Research Center finds that in some cases a mismatched donor may work for leukemia patients — expanding the donor pool and increasing opportunity for people seeking lifesaving treatment